Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PHASEBIO PHARMACEUTICALS, INC.

(PHAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PhaseBio Pharmaceuticals, Inc.(NasdaqGM:PHAS) added to S&P Global BMI Index

09/20/2021 | 12:00am EDT

PhaseBio Pharmaceuticals, Inc.(NasdaqGM:PHAS) added to S&P Global BMI Index


ę S&P Capital IQ 2021
All news about PHASEBIO PHARMACEUTICALS, INC.
10/06PHASEBIO PHARMACEUTICALS : to Present Late-Stage Bentracimab Trial Results Nov. 15, Plans ..
MT
10/06PHASEBIO PHARMACEUTICALS : Announces Interim Analysis of REVERSE-IT Phase 3 Trial Accepted..
BU
09/20PHASEBIO PHARMACEUTICALS, INC.(NASDA : PHAS) added to S&P Global BMI Index
CI
09/15PHASEBIO PHARMACEUTICALS : Appoints William D. Humphries to Board of Directors (Form 8-K)
PU
09/15PHASEBIO PHARMACEUTICALS INC : Change in Directors or Principal Officers, Regulation FD Di..
AQ
09/15PhaseBio Pharmaceuticals, Inc. Announces Board Changes
CI
09/15PHASEBIO PHARMACEUTICALS : Appoints William D. Humphries to Board of Directors
BU
08/31PHASEBIO PHARMACEUTICALS : to Present at 23rd Annual H.C. Wainwright Global Investment Con..
BU
08/12PHASEBIO PHARMACEUTICALS : Achieved interim enrollment milestone with first 143 bentracima..
PU
08/12PHASEBIO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and..
AQ
More news
Analyst Recommendations on PHASEBIO PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 12,6 M - -
Net income 2021 -117 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,51x
Yield 2021 -
Capitalization 185 M 185 M -
Capi. / Sales 2021 14,7x
Capi. / Sales 2022 11,6x
Nbr of Employees 55
Free-Float 93,0%
Chart PHASEBIO PHARMACEUTICALS, INC.
Duration : Period :
PhaseBio Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHASEBIO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 3,85 $
Average target price 14,50 $
Spread / Average Target 277%
EPS Revisions
Managers and Directors
Jonathan P. Mow Chief Executive Officer & Director
John P. Sharp Chief Financial Officer
Clay Bernardin Thorp Executive Chairman
John S. Lee Chief Medical Officer
Nancy J. Hutson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PHASEBIO PHARMACEUTICALS, INC.14.58%185
GILEAD SCIENCES, INC.16.25%84 921
BIONTECH SE258.67%70 618
WUXI APPTEC CO., LTD.23.63%64 231
REGENERON PHARMACEUTICALS22.57%61 565
VERTEX PHARMACEUTICALS-22.12%47 753